Application of PBPK modeling to predict human intestinal metabolism of CYP3A substrates - An evaluation and case study using GastroPlus™

European Journal of Pharmaceutical Sciences

Volumn 47, Issue 2, 2012, Pages 375-386

  Heikkinen, Aki T ^a   Baneyx, Guillaume ^a   Caruso, Antonello ^a   Parrott, Neil ^a  

^a F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

Binding in enterocytes; Gut wall metabolism; Monte Carlo simulation; Physiologically based pharmacokinetic modeling; Propagation of error

Indexed keywords

ALFENTANIL; ATORVASTATIN; BUSPIRONE; CISAPRIDE; CYCLOSPORIN A; CYTOCHROME P450 3A; DILTIAZEM; FELODIPINE; INDINAVIR; MEVINOLIN; MIDAZOLAM; NIFEDIPINE; NIMODIPINE; NISOLDIPINE; QUINIDINE; SAQUINAVIR; SIMVASTATIN; TACROLIMUS; TERFENADINE; TRIAZOLAM; VERAPAMIL;

ACCURACY; ARTICLE; CELL MEMBRANE PERMEABILITY; COMPUTER MODEL; COMPUTER PROGRAM; DECISION MAKING; DISSOLUTION; DRUG ABSORPTION; DRUG PENETRATION; DRUG SOLUBILITY; ENZYME SUBSTRATE; HUMAN; HUMAN CELL; IN VITRO STUDY; INTESTINE METABOLISM; LIVER MICROSOME; METABOLIC CLEARANCE RATE; METABOLISM; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SENSITIVITY ANALYSIS;

COMPUTER SIMULATION; CYTOCHROME P-450 CYP3A; HUMANS; INTESTINES; MODELS, BIOLOGICAL; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS; REPRODUCIBILITY OF RESULTS; SOFTWARE;

EID: 84864414534     PISSN: 09280987     EISSN: 18790720     Source Type: Journal    
DOI: 10.1016/j.ejps.2012.06.013     Document Type: Article

References (89)

1. B.S. Abuasal, M.B. Bolger, D.K. Walker, and A. Kaddoumi In silico modeling for the nonlinear absorption kinetics of UK-343,664: a P-gp and CYP3A4 substrate Mol. Pharm. 9 2012 492 504
2. B. Agoram, W.S. Woltosz, and M.B. Bolger Predicting the impact of physiological and biochemical processes on oral drug bioavailability Adv Drug Deliv Rev 50 2001 S41 S67
3. M. Al Omari, M. Zughul, J. Davies, and A. Badwan Thermodynamic enthalpy-entropy compensation effects observed in the complexation of basic drug substrates with β-cyclodextrin J. Incl. Phenom. Macrocycl. Chem. 57 2007 379 384
4. J. Alsenz, and E. Haenel Development of a 7-day, 96-well Caco-2 permeability assay with high-throughput direct UV compound analysis Pharm Res 20 2003 1961 1969
5. A. Avdeef Solubility of sparingly-soluble ionizable drugs Adv. Drug. Deliv. Rev. 59 2007 568 590
6. Z.E. Barter, J.E. Chowdry, J.R. Harlow, J.E. Snawder, J.C. Lipscomb, and A. Rostami-Hodjegan Covariation of human microsomal protein per gram of liver with age: absence of influence of operator and sample storage may justify interlaboratory data pooling Drug Metab. Dispos. 36 2008 2405 2409
7. L.Z. Benet The drug transporter-metabolism alliance. Uncovering and defining the interplay Mol. Pharm. 6 2009 1631 1643
8. R.K. Bhardwaj, H. Glaeser, L. Becquemont, U. Klotz, S.K. Gupta, and M.F. Fromm Piperine, a major constituent of black pepper, inhibits human P-glycoprotein and CYP3A4 J. Pharmacol. Exp. Ther. 302 2002 645 650
9. N. Blagden, M. de Matas, P.T. Gavan, and P. York Crystal engineering of active pharmaceutical ingredients to improve solubility and dissolution rates Adv. Drug. Deliv. Rev. 59 2007 617 630
10. H. Bohets, K. Lavrijsen, J. Hendrickx, J. Van Houdt, V. Van Genechten, P. Verboven, W. Meuldermans, and J. Heykants Identification of the cytochrome P450 enzymes involved in the metabolism of cisapride: in vitro studies of potential co-medication interactions Br J. Pharmacol. 129 2000 1655 1667
11. H.S. Brown, M. Griffin, and J.B. Houston Evaluation of cryopreserved human hepatocytes as an alternative in vitro system to microsomes for the prediction of metabolic clearance Drug Metab. Dispos. 35 2007 293 301
12. W.L. Chiou, and P.W. Buehler Comparison of oral absorption and bioavailability of drugs between monkey and human Pharm. Res. 19 2002 868 874
13. S. Clarysse, J. Brouwers, J. Tack, P. Annaert, and P. Augustijns Intestinal drug solubility estimation based on simulated intestinal fluids: comparison with solubility in human intestinal fluids Eur. J. Pharm. Sci. 43 2011 260 269
14. D. Cong, M. Doherty, and K.S. Pang A new physiologically based, segregated-flow model to explain route-dependent intestinal metabolism Drug Metab. Dispos. 28 2000 224 235
15. H.E. Cubitt, K.R. Yeo, E.M. Howgate, A. Rostami-Hodjegan, and Z.E. Barter Sources of interindividual variability in IVIVE of clearance. an investigation into the prediction of benzodiazepine clearance using a mechanistic population-based pharmacokinetic model Xenobiotica 41 2011 623 638
16. C. Dagenais, A. Avdeef, O. Tsinman, A. Dudley, and R. Beliveau P-glycoprotein deficient mouse in situ blood-brain barrier permeability and its prediction using an in combo PAMPA model Eur. J. Pharm. Sci. 38 2009 121 137
17. P. Damkier, L.L. Hansen, and K. Brøsen Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine Br. J. Clin. Pharmacol. 48 1999 829 838
18. A.S. Darwich, S. Neuhoff, M. Jamei, and A. Rostami-Hodjegan Interplay of metabolism and transport in determining oral drug absorption and gut wall metabolism: a simulation assessment using the advanced dissolution, absorption, metabolism (ADAM) model Curr. Drug Metab. 11 2010 716 729
19. S.S. De Buck, and C.E. Mackie Physiologically based approaches towards the prediction of pharmacokinetics: in vitro-in vivo extrapolation Expert Opin Drug Metab. Toxicol. 3 2007 865 878
20. F. Fenneteau, P. Poulin, and F. Nekka Physiologically based predictions of the impact of inhibition of intestinal and hepatic metabolism on human pharmacokinetics of CYP3A substrates J. Pharm. Sci. 99 2010 486 514
21. U. Fuhr, A. Maier-Bruggemann, H. Blume, W. Muck, S. Unger, J. Kuhlmann, C. Huschka, M. Zaigler, S. Rietbrock, and A.H. Staib Grapefruit juice increases oral nimodipine bioavailability Int. J. Clin. Pharmacol. Ther. 36 1998 126 132
22. A. Galetin, M. Gertz, and J.B. Houston Potential role of intestinal first-pass metabolism in the prediction of drug-drug interactions Expert Opin Drug Metab. Toxicol. 4 2008 909 922
23. M. Gertz, J.D. Davis, A. Harrison, J.B. Houston, and A. Galetin Grapefruit juice-drug interaction studies as a method to assess the extent of intestinal availability: utility and limitations Curr. Drug Metab. 9 2008 785 795
24. M. Gertz, A. Harrison, J.B. Houston, and A. Galetin Prediction of human intestinal first-pass metabolism of 25 CYP3A substrates from in vitro clearance and permeability data Drug Metab. Dispos. 38 2010 1147 1158
25. M. Gertz, J.B. Houston, and A. Galetin Physiologically-based pharmacokinetic modeling of intestinal first-pass metabolism of CYP3A substrates with high intestinal extraction Drug Metab. Dispos. 39 2011 1633 1642
26. A.S. Gross, Y.D. Goh, R.S. Addison, and G.M. Shenfield Influence of grapefruit juice on cisapride pharmacokinetics[ast] Clin. Pharmacol. Ther. 65 1999 395 401
27. F.P. Guengerich Cytochrome P450s and other enzymes in drug metabolism and toxicity AAPS J. 8 2006 E101 111
28. P.-C. Ho, K. Ghose, D. Saville, and S. Wanwimolruk Effect of grapefruit juice on pharmacokinetics and pharmacodynamics of verapamil enantiomers in healthy volunteers Eur. J. Clin. Pharmacol. 56 2000 693 698
29. N. Holtbecker, M.F. Fromm, H.K. Kroemer, E.E. Ohnhaus, and H. Heidemann The nifedipine-rifampin interaction. Evidence for induction of gut wall metabolism Drug Metab. Dispos. 24 1996 1121 1123
30. L.D. Hughes, D.S. Palmer, F. Nigsch, and J.B.O. Mitchell Why are some properties more difficult to predict than others? a study of QSPR models of solubility, melting point, and log P J. Chem. Inf. Model 48 2008 220 232
31. S.K. Hukkinen, A. Varhe, K.T. Olkkola, and P.J. Neuvonen Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice Clin. Pharmacol. Ther. 58 1995 127 131
32. M.N. Iskander, L.M. Leung, T. Buley, F. Ayad, J. Di Iulio, Y.Y. Tan, and I.M. Coupar Optimization of a pharmacophore model for 5-HT4 agonists using CoMFA and receptor based alignment Eur. J. Med. Chem. 41 2006 16 26
33. M. Jamei, G.L. Dickinson, and A. Rostami-Hodjegan A framework for assessing inter-individual variability in pharmacokinetics using virtual human populations and integrating general knowledge of physical chemistry, biology, anatomy, physiology and genetics: a tale of 'bottom-up' vs. 'top-down' recognition of covariates Drug Metab. Pharmacokinet. 24 2009 53 75
34. M. Jamei, D. Turner, J. Yang, S. Neuhoff, S. Polak, A. Rostami-Hodjegan, and G. Tucker Population-based mechanistic prediction of oral drug absorption AAPS J. 11 2009 225 237
35. R. Jansson, U. Bredberg, and M. Ashton Prediction of drug tissue to plasma concentration ratios using a measured volume of distribution in combination with lipophilicity J. Pharm. Sci. 97 2008 2324 2339
36. T.N. Johnson, G.T. Tucker, M.S. Tanner, and A. Rostami-Hodjegan Changes in liver volume from birth to adulthood: a meta-analysis Liver Transplant. 11 2005 1481 1493
37. H.M. Jones, N. Parrott, K. Jorga, and T. Lave A novel strategy for physiologically based predictions of human pharmacokinetics Clin. Pharmacokinet. 45 2006 511 542
38. H.M. Jones, I.B. Gardner, W.T. Collard, P.J. Stanley, P. Oxley, N.A. Hosea, D. Plowchalk, S. Gernhardt, J. Lin, M. Dickins, S.R. Rahavendran, B.C. Jones, K.J. Watson, H. Pertinez, V. Kumar, and S. Cole Simulation of human intravenous and oral pharmacokinetics of 21 diverse compounds using physiologically based pharmacokinetic modelling Clin. Pharmacokinet. 50 2011 331 347
39. E.D. Kharasch, S. Vangveravong, N. Buck, A. London, T. Kim, J. Blood, and R.H. Mach Concurrent assessment of hepatic and intestinal cytochrome P450 3A activities using deuterated alfentanil Clin. Pharmacol. Ther. 89 2011 562 570
40. A. Kokate, X. Li, P. Williams, P. Singh, and B. Jasti Prediction of drug permeability across buccal mucosa Pharm. Res. 26 2009 1130 1139
41. J.C. Kolars, W.M. Awni, R.M. Merion, and P.B. Watkins First-pass metabolism of cyclosporin by the gut Lancet 338 1991 1488 1490
42. M. Konishi, K. Hirai, and Y. Mori Kinetics and mechanism of the equilibrium reaction of triazolam in aqueous solution J. Pharm. Sci. 71 1982 1328 1334
43. K.L. Lavrijsen, J.M. Van Houdt, D.M. Van Dyck, J.J. Hendrickx, R.J. Woestenborghs, W. Lauwers, W.E. Meuldermans, and J.J. Heykants Is the metabolism of alfentanil subject to debrisoquine polymorphism? a study using human liver microsomes Anesthesiology 69 1988 535 540
44. H. Lennernäs Intestinal permeability and its relevance for absorption and elimination Xenobiotica 37 2007 1015 1051
45. J.H. Lin, M. Chiba, and T.A. Baillie Is the role of the small intestine in first-pass metabolism overemphasized Pharmacol. Rev. 51 1999 135 158
46. X.Q. Liu, Y.L. Ren, Z.Y. Qian, and G.J. Wang Enzyme kinetics and inhibition of nimodipine metabolism in human liver microsomes Acta Pharmacol. Sinic. 21 2000 690 694
47. K.S. Lown, J.C. Kolars, K.E. Thummel, J.L. Barnett, K.L. Kunze, S.A. Wrighton, and P.B. Watkins Interpatient heterogeneity in expression of CYP3A4 and CYP3A5 in small bowel. Lack of prediction by the erythromycin breath test Drug Metab. Dispos. 22 1994 947 955
48. A. Lu, M. Frisella, and K. Johnson Dissolution modeling: factors affecting the dissolution rates of polydisperse powders Pharm. Res. 10 1993 1308 1314
49. S.D. Mithani, V. Bakatselou, C.N. TenHoor, and J.B. Dressman Estimation of the increase in solubility of drugs as a function of bile salt concentration Pharm. Res. 13 1996 163 167
50. D.R. Mudra, P.V. Desai, and K.E. Desino In silico, in vitro andin situ models to assess interplay between CYP3A and P-gp Curr. Drug Metab. 2011
51. H. Nishimuta, K. Sato, Y. Mizuki, M. Yabuki, and S. Komuro Prediction of the intestinal first-pass metabolism of CYP3A substrates in humans using cynomolgus monkeys Drug Metab. Dispos. 2010
52. H. Nishimuta, K. Sato, M. Yabuki, and S. Komuro Prediction of the intestinal first-pass metabolism of CYP3A and UGT substrates in humans from in vitro data Drug Metab. Pharmacokinet. 2011 10
53. A. Okazaki, T. Mano, and K. Sugano Theoretical dissolution model of poly-disperse drug particles in biorelevant media J. Pharm. Sci. 97 2008 1843 1852
54. K.T. Olkkola, K. Aranko, H. Luurila, A. Hiller, L. Saarnivaara, J.J. Himberg, and P.J. Neuvonen A potentially hazardous interaction between erythromycin and midazolam Clin. Pharmacol. Ther. 53 1993 298 305
55. M.F. Paine, D.D. Shen, K.L. Kunze, J.D. Perkins, C.L. Marsh, J.P. McVicar, D.M. Barr, B.S. Gillies, and K.E. Thummel First-pass metabolism of midazolam by the human intestine Clin. Pharmacol. Ther. 60 1996 14 24
56. M.F. Paine, M. Khalighi, J.M. Fisher, D.D. Shen, K.L. Kunze, C.L. Marsh, J.D. Perkins, and K.E. Thummel Characterization of interintestinal and intraintestinal variations in human CYP3A-dependent metabolism J. Pharmacol. Exp. Ther. 283 1997 1552 1562
57. M.F. Paine, H.L. Hart, S.S. Ludington, R.L. Haining, A.E. Rettie, and D.C. Zeldin The human intestinal cytochrome P450 "pie" Drug Metab. Dispos. 34 2006 880 886
58. N. Parrott, and T. Lave Applications of physiologically based absorption models in drug discovery and development Mol. Pharm. 5 2008 760 775
59. Parrott, N., Lave, T. 2010. Computer models for predicting drug absorption. In: J.B. Dressman, C. Reppas (Eds.), Oral Drug Absorption, pp. 338-355 (Informa).
60. N. Parrott, N. Paquereau, P. Coassolo, and T. Lave An evaluation of the utility of physiologically based models of pharmacokinetics in early drug discovery J. Pharm. Sci. 94 2005 2327 2343
61. K.C. Patki, L.L. Von Moltke, and D.J. Greenblatt In vitro metabolism of midazolam, triazolam, nifedipine, and testosterone by human liver microsomes and recombinant cytochromes p450: role of cyp3a4 and cyp3a5 Drug Metab. Dispos. 31 2003 938 944
62. O. Pelkonen, and M. Turpeinen In vitro-in vivo extrapolation of hepatic clearance. biological tools, scaling factors, model assumptions and correct concentrations Xenobiotica 37 2007 1066 1089
63. E. Persson, A.-S. Gustafsson, A. Carlsson, R. Nilsson, L. Knutson, P. Forsell, G. Hanisch, H. Lennernäs, and B. Abrahamsson The effects of food on the dissolution of poorly soluble drugs in human and in model small intestinal fluids Pharm. Res. 22 2005 2141 2151
64. A. Poirier, C. Funk, J.M. Scherrmann, and T. Lave Mechanistic modeling of hepatic transport from cells to whole body: application to napsagatran and fexofenadine Mol. Pharm. 6 2009 1716 1733
65. T.J. Rashid, U. Martin, H. Clarke, D.G. Waller, A.G. Renwick, and C.F. George Factors affecting the absolute bioavailability of nifedipine Br. J. Clin. Pharmacol. 40 1995 51 58
66. B.G. Reigner, P.E. Williams, I.H. Patel, J.L. Steimer, C. Peck, and P. van Brummelen An evaluation of the integration of pharmacokinetic and pharmacodynamic principles in clinical drug development. Experience within Hoffmann La Roche Clin. Pharmacokinet. 33 1997 142 152
67. T. Rodgers, and M. Rowland Mechanistic approaches to volume of distribution predictions: understanding the processes Pharm. Res. 24 2007 918 933
68. M. Rowland, C. Peck, and G. Tucker Physiologically-based pharmacokinetics in drug development and regulatory science Ann. Rev. Pharmacol. Toxicol. 51 2011 45 73
69. G. Sathyan, M.B. Chancellor, and S.K. Gupta Effect of OROS controlled-release delivery on the pharmacokinetics and pharmacodynamics of oxybutynin chloride Br. J. Clin. Pharmacol. 52 2001 409 417
70. H. Sigusch, L. Henschel, H. Kraul, U. Merkel, and A. Hoffmann Lack of effect of grapefruit juice on diltiazem bioavailability in normal subjects Pharmazie 49 1994 675 679
71. SimulationsPlus, 2010a. ADMET PredictorTM manual, version 5.0.
72. SimulationsPlus, 2010b. GastroPlusTM manual, version 7.0.
73. V.K. Sinha, J. Snoeys, N.V. Osselaer, A.V. Peer, C. Mackie, and D. Heald From preclinical to human - prediction of oral absorption and drug-drug interaction potential using physiologically based pharmacokinetic (PBPK) modeling approach in an industrial setting: a workflow by using case example Biopharm. Drug Dispos. 33 2012 111 121
74. E. Söderlind, E. Karlsson, A. Carlsson, R. Kong, A. Lenz, S. Lindborg, and J.J. Sheng Simulating fasted human intestinal fluids: understanding the roles of lecithin and bile acids Mol. Pharm. 2010 10
75. T. Tachibana, M. Kato, J. Takano, and Y. Sugiyama Predicting drug-drug interactions involving the inhibition of intestinal CYP3A4 and P-glycoprotein Curr. Drug Metab. 11 2010 762 777
76. M. Takahashi, T. Washio, N. Suzuki, K. Igeta, and S. Yamashita The species differences of intestinal drug absorption and first-pass metabolism between cynomolgus monkeys and humans J. Pharm. Sci. 98 2009 4343 4353
77. D. Tam, R.G. Tirona, and K.S. Pang Segmental intestinal transporters and metabolic enzymes on intestinal drug absorption Drug Metab. Dispos. 31 2003 373 383
78. M. Tubic-Grozdanis, J. Hilfinger, G. Amidon, J. Kim, P. Kijek, P. Staubach, and P. Langguth Pharmacokinetics of the CYP 3A Substrate simvastatin following administration of delayed vs. immediate release oral dosage forms Pharm. Res. 25 2008 1591 1600
79. R.A. van Waterschoot, and A.H. Schinkel A critical analysis of the interplay between cytochrome P450 3A and P-glycoprotein: recent insights from knockout and transgenic mice Pharmacol. Rev. 63 2011 390 410
80. M.V. Varma, R.S. Obach, C. Rotter, H.R. Miller, G. Chang, S.J. Steyn, A. El-Kattan, and M.D. Troutman Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination J. Med. Chem. 53 2010 1098 1108
81. T. Vasconcelos, B. Sarmento, and P. Costa Solid dispersions as strategy to improve oral bioavailability of poor water soluble drugs Drug Discov. Today 12 2007 1068 1075
82. O. von Richter, B. Greiner, M.F. Fromm, R. Fraser, T. Omari, M.L. Barclay, J. Dent, A.A. Somogyi, and M. Eichelbaum Determination of in vivo absorption, metabolism, and transport of drugs by the human intestinal wall and liver with a novel perfusion technique Clin. Pharmacol. Ther. 70 2001 217 227
83. O. von Richter, O. Burk, M.F. Fromm, K.P. Thon, M. Eichelbaum, and K.T. Kivisto Cytochrome P450 3A4 and P-glycoprotein expression in human small intestinal enterocytes and hepatocytes: a comparative analysis in paired tissue specimens Clin. Pharmacol. Ther. 75 2004 172 183
84. S. Winiwarter, N.M. Bonham, F. Ax, A. Hallberg, H. Lennernäs, and A. Karlen Correlation of human jejunal permeability (in vivo) of drugs with experimentally and theoretically derived parameters. A multivariate data analysis approach J. Med. Chem. 41 1998 4939 4949
85. J.S. Yang, A. Rostami-Hodjegan, and G.T. Tucker Prediction of ketoconazole interaction with midazolam, alprazolam and triazolam: incorporating population variability Br. J. Clin. Pharmacol. 52 2001 472P
86. J. Yang, M. Jamei, K.R. Yeo, G.T. Tucker, and A. Rostami-Hodjegan Prediction of intestinal first-pass drug metabolism Curr. Drug Metab. 8 2007 676 684
87. L.X. Yu, and G.L. Amidon A compartmental absorption and transit model for estimating oral drug absorption Int. J. Pharm. 186 1999 119 125
88. P. Zhao, C.A. Lee, and K.L. Kunze Sequential metabolism is responsible for diltiazem-induced time-dependent loss of CYP3A Drug Metab. Dispos. 35 2007 704 712
89. P. Zhao, L. Zhang, J.A. Grillo, Q. Liu, J.M. Bullock, Y.J. Moon, P. Song, S.S. Brar, R. Madabushi, T.C. Wu, B.P. Booth, N.A. Rahman, K.S. Reynolds, E. Gil Berglund, L.J. Lesko, and S.M. Huang Applications of physiologically based pharmacokinetic (PBPK) modeling and simulation during regulatory review Clin. Pharmacol. Ther. 89 2011 259 267